Estonia vs Mus: HIV-positive TB patients on ART (antiretroviral therapy)
Estonia
100.0%
in 2024
Mus
100.0%
in 2024
Estonia rank
1st
Mus rank
1st
HIV-positive TB patients on ART (antiretroviral therapy) over time
- Estonia
- Mus
How they compare
Estonia currently reports 100.0% against 100.0% in Mus, a difference of 0.0%.
The two have swapped places 4 times across 17 shared years of data; in 2008 it was Mus ahead.
Estonia ranks 1st and Mus ranks 1st of 144 countries.
Mus has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Estonia | Mus | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 45.5% | 60.5% | 15.0% | Mus |
| 2010s | 76.8% | 86.2% | 9.4% | Mus |
| 2020s | 93.2% | 100.0% | 6.8% | Mus |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv-positive tb patients on art (antiretroviral therapy), Estonia or Mus?
- Estonia, at 100.0% against 100.0% in Mus as of 2024.
- What is the difference in hiv-positive tb patients on art (antiretroviral therapy) between Estonia and Mus?
- 0.0%, with Estonia ahead.
- How many years of comparable data are there for Estonia and Mus?
- 17 years are reported by both, from 2008 to 2024.
- How do Estonia and Mus rank globally for hiv-positive tb patients on art (antiretroviral therapy)?
- Estonia ranks 1st and Mus ranks 1st of 144 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as HIV-positive TB patients on ART (antiretroviral therapy) (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.